Low rate of compliance with ergocalciferol therapy in vitamin-D-deficient patients with hip fracture

Jane M Noble, Marjory McGuiness and Paul Glendenning
Med J Aust 2002; 177 (5): . || doi: 10.5694/j.1326-5377.2002.tb04775.x
Published online: 2 September 2002

To the editor: Large randomised trials have confirmed that treatment with cholecalciferol (vitamin D3) and calcium reduces hip and non-vertebral fractures.1,2 In public health terms, calciferol compounds are cost-effective,3 simple to monitor and generally free of side effects. Ergocalciferol (vitamin D2) is the only single prohormonal form of vitamin D available in Australia.4 As compliance rates for this medication have not, to our knowledge, been evaluated, we decided to conduct our own study of compliance.

  • Jane M Noble
  • Marjory McGuiness
  • Paul Glendenning


The authors wish to acknowledge the help of Dr Peter Goldswain, Department of Geriatrics, Royal Perth Hospital, for assistance with patient access.

Competing interests:

None declared.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.